Rakovina Therapeutics Inc (RKV) — Working Capital to Net Assets Ratio
Rakovina Therapeutics Inc (RKV) has a Working Capital to Net Assets ratio of -25.9% as of September 2025. Working capital of CA$-489.28K (current assets of CA$1.69 Million minus current liabilities of CA$2.18 Million) is measured against net assets of CA$1.89 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See financial agility of Rakovina Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Rakovina Therapeutics Inc Working Capital to Net Assets (2021–2024)
This chart shows how Rakovina Therapeutics Inc's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of September 2025, the ratio stands at -25.9%, reflecting working capital of CA$-489.28K against net assets of CA$1.89 Million CAD. See RKV defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Rakovina Therapeutics Inc (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Rakovina Therapeutics Inc from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see RKV stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (CAD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 7.5% | CA$321.44K | CA$4.30 Million | CA$2.26 Million | CA$1.94 Million | ▼ -5.6 pp |
| 2023 | 13.1% | CA$477.88K | CA$3.66 Million | CA$632.53K | CA$154.65K | ▼ -2.9 pp |
| 2022 | 16.0% | CA$962.55K | CA$6.01 Million | CA$1.07 Million | CA$107.05K | ▼ -18.6 pp |
| 2021 | 34.6% | CA$2.96 Million | CA$8.54 Million | CA$3.07 Million | CA$113.98K | — |